10/12/2021 10:03:28 AM
Hoth Therapeutics Gets Approval To Commence Cohort 2 In Trial Of BioLexa For Treatment Of Atopic Dermatitis Patients
9/21/2021 10:07:19 AM
Hoth Submits To Ethics Committee For Approval To Initiate Patient Cohort 2 In BioLexa Clinical Trial
9/8/2021 8:10:55 AM
Hoth Therapeutics Announces Positive Phase 1b Results From First Cohort Of Patient Trial Of BioLexa
8/2/2021 8:16:59 AM
Hoth Therapeutics Initiates Preclinical Study Of HT-ALZ For Alzheimer's Disease
7/13/2021 8:18:42 AM
Hoth Therapeutics: HT-003 Group Of Assets Yields Positive Results In An In Vivo Acne Therapeutic Model
6/28/2021 8:12:00 AM
Hoth Therapeutics Announces Positive Results From AD001 Cohort 1 Of Phase 1b Trial Of BioLexa For Atopic Dermatitis
6/3/2021 8:09:32 AM
Hoth Therapeutics Shares Positive Preclinical Results Of Novel HT-KIT Therapeutic
5/5/2021 9:27:33 AM
Hoth Therapeutics, Virginia Commonwealth University Expand Research Agreement For COVID-19 Therapeutic
4/22/2021 9:13:55 AM
Hoth Says Its First In Human Clinical Trial For Treatment Of Atopic Dermatitis With BioLexa Underway
4/20/2021 9:12:02 AM
Hoth Announces MRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth In Mast Cell-Derived Cancers
4/6/2021 9:20:16 AM
Hoth Engages Clinical Trials As Contract Research Organization For Phase 2a HT-001 Trial For Cancer Patients
4/5/2021 8:20:15 AM
Hoth Announces Notice Of Allowance For New Patent Application Related To Method For Inhibiting Formation Of Biofilm
3/24/2021 8:28:33 AM
Voltron Therapeutics Reports Positive Data From Animal Testing Of Its HaloVax SAV Against COVID-19